GHRP-2 Found in Black Market Nutritional Supplements Flagged by Cologne Doping Lab 2009
Background
Doping in sport represents a persistent challenge for anti-doping laboratories, which must continuously track emerging substances appearing on black markets and in nutritional supplements before formal regulatory scheduling or widespread athlete testing occurs. The growth hormone (GH) axis is a prime target for performance enhancement, with peptides such as GHRP-2 stimulating endogenous GH release via the GHSR pathway, circumventing direct GH detection. Nutritional supplements are a documented vector for undisclosed pharmacologically active compounds, creating detection blind spots. The lag between a substance's appearance on illicit markets and the availability of validated detection methods leaves athletes and regulators in an asymmetric information environment that surveillance of black-market products is designed to close.
Study Design
The Cologne Doping Control Laboratory performed a structured analytical survey of confiscated black market products and commercially obtained nutritional supplements collected throughout 2009. Ingredients were identified using liquid chromatography coupled with mass spectrometry (LC-MS) methods. Products screened included injection vials, ampoules, and oral supplement formulations. No controlled administration study or human participant cohort was described; the work is a forensic product-composition analysis.
Results
Several categories of pharmacologically relevant findings were documented across the product set. GH-labelled injection vials were found to contain no pharmacologically active content, indicating deliberate fraud or contamination in the supply chain. Combinations of products were identified that appeared designed to mask growth hormone abuse, suggesting sophisticated multi-compound doping strategies. Unpurified long-R(3)-IGF-1 was detected in one or more products, raising concerns about quality and safety of illicitly sourced peptides. Nutritional supplements were confirmed to contain growth hormone releasing peptide-2 (GHRP-2), a peptide not approved for human use in supplement form.
Ampoules containing the selective androgen receptor modulator Andarine (S-4) — still under clinical investigation at the time — were also identified, highlighting that investigational drugs were circulating through black market channels.
All detections were made by LC-MS, confirming the analytical reliability of the identifications.
Key Findings
- GH-labelled injection vials contained no pharmacologically active ingredient
- GHRP-2 was identified in commercially obtainable nutritional supplements
- Unpurified long-R(3)-IGF-1 detected in confiscated products
- Andarine (S-4), an investigational SARM, found in confiscated ampoules
- Product combinations consistent with deliberate GH-abuse masking strategies identified
Why It Matters
Finding GHRP-2 in commercially available nutritional supplements means athletes and consumers may be unknowingly ingesting a non-approved peptide with systemic GH-releasing activity, creating both unintentional doping violations and uncharacterized safety exposure. For biohackers and performance-oriented users, the data underscore that black market and supplement-sourced peptides are frequently mislabelled, absent of active ingredient, or contaminated with unapproved compounds. Anti-doping laboratories must proactively surveil black market products to close the method-development gap before new substances proliferate in tested populations. The co-detection of masking agents alongside GH-axis peptides signals that sophisticated stacking strategies were already in use by 2009, with implications for how detection protocols should be layered.
